CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3^{RO} FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

 CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K WEBSITE: www.thechemopharmalaboratoriesltd.com EMAIL ID: chemopharmalab@gmail.com

Date: 21st January, 2016

To, Bombay Stock Exchange Ltd. Department of Corporate Services 25th Floor, P.J.Towers, Dalal Street, Mumbai-400 001

Script ID

: 506365

Subject

: SUBMISSION OF COMPLIANCES UNDER SECURITIES AND

EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND

DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 for Quarter ended 31st December, 2015 as under -

1.	Regulation 33	Un-audited Quarterly Financial Results, for the Quarter ended 31/12/2015 along with Limited Review Report issued by our Auditors M/s. Batliboi & Purohit, Chartered Accountant, Mumbai			
2.		Outcome of the Board Meeting Held on 21/01/2016			

You are requested to take this on your records and acknowledge receipt.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED

ASHOK SOMANI DIRECTOR

(DIN NO. - 03063364)

CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K

WEBSITE: www.thechemopharmalaboratoriesltd.com EMAIL ID: chemopharmalab@gmail.com

ANNEXURE - I

Part I

(Rs. In Thousand)

Statement of Standalone Results for the Quarter and Nine Months ended 31/12/2015

Sr. No.	Particulars		3 Months ended 31/12/2015	Preceding 3 Months ended 30/09/2015	Corresponding 3 Months ended in the previous year 31/12/2014	Year to date figures for Current period ended 31/12/2015	Year to date figures for previous year ended 31/12/2014	Previous Year Ended 31/03/2015
			Unaudited	Unaudited	Unaudited	Unaudited	Audited	Audited
1	Inc	ome from Operations						
	a.	Net Sales/ Income from Operation (Net of Excise Duty)	-	-	-	-	-	
	b.	Other Operating Income	326	1,263	325	2,374	2,563	5,044
	To	tal Income from Operations (Net)	326	1,263	325	2,374	2,563	5,044
2	Expenses							
	a.	Cost Materials consumed	-	-	-		-	-
	b.	Purchase of Stock-in-Trade		THE PROPERTY AND ADDRESS OF		-	-	
	c.	Changes in Inventories of Finished Goods, Work- in-Progress and Stock-in-Trade	-	-	-			- 33331733-
	d.	Employee Benefits Expenses	152	129	96	392	192	305
	e.	Depreciation and Amortisation Expenses	- 102	-	16	- 0,2	27	-
		Other Expenses (Any Item exceeding 10% of the	18	146	(103)	178	208	242
		i) Professional Charges	36	90	45	136	107	448
		ii) Share Registry Expenses	35			72	64	
		iii) Annual Listing Fees	10		125	235	125	125
	To	otal Expenses	251	383	199	1,013	723	1,205
3	Inc	ofit/(Loss) from Operation before Other come, Finance Costs and Exceptional ms (1-2)	75	880	127	1,361	1,840	3,839
4	Ot	her Income	Establish -	-		-	-	
5	Profit/(Loss) from Ordinary Activities before Finance Costs and Exceptional Items (3+/-4)		75	880	127	1,361	1,840	3,839
6	Fin	nance Costs	-					-
7	Profit/(Loss) from Ordinary Activities after Finance Costs but before Exceptional Items (5+/-6)		75	880	127	1,361	1,840	3,839
8	Ex	sceptional Items	-	-				
9	Pr	rofit/(Loss) from Ordinary Activities before x (7+/-8)	75	880	127	1,361	1,840	3,839
10	-	x Expenses					1.2	1,040
11	Net Profit/(Loss) from ordinary Activities after Tax (9+/-10)		75	880	127	1,361	1,840	
12	Extra Ordinary Items (Net of Tax Expenses		-	-	Satilian -	Marginia.		
13	-	et Profit/(Loss) for the Period (11+/-12)	75	880	127	1,361	1,840	2,799
14			-			-		-
15			-	-	-	-	-	-
	Net Profit/(Loss) after Taxes, Minority Interest and Share of Profit /(Loss) of Associates (13+/-14+/-15)*		75		127		1,840	2,799



Contd... 2

CHEMO PHARMA LABORATORIES LIMITED

REGISTERED OFFICE: 5-KUMUD APARTMENT CO. OP. HSG. SOC. LTD., KARNIK ROAD, CHIKAN GHAR, KALYAN, DIST. THANE- 421301

• CORPORATE OFFICE- EMPIRE HOUSE, 3RD FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001

• TEL NO.: (022) 22078381, 22078382 • FAX NO.: (022)22074294

 CIN NO.: L99999MH1942PLC003556 • PAN NO.: AAACC2056K WEBSITE: www.thechemopharmalaboratoriesltd.com

EMAIL ID: chemopharmalab@gmail.com

: Page 2 :

17	Paid-up Capital Equity Share (Face Value of Rs.10/- each)	15,000	15,000	15,000	15,000	15,000	15,000			
18	Reserves excluding Revaluation Reserve as per Balance Sheet of Previous Accounting Year	37,503	37,503	35,210	37,503	35,210	36,217			
	Earnings per Share (before Extra Ordinary Items) (of Rs/- each) (not Annualised): a. Basic b. Diluted	0.05	0.59	0.08	0.91	1.23	1.87			
	Earnings per Share (after Extra Ordinary Items) (of Rs/- each) (not Annualised): a. Basic b. Diluted	0.05	0.59	0.08	0.91	1.23	1.87			
A	PARTICULARS OF SHAREHOLDING									
1	Public Shareholding									
	- Number of shares	10,81,719	10,81,719	10,81,719	10,81,719	10,81,719	10,81,719			
	- Percentage of shareholding	72.12	72.12	72.12	72.12	72.12	72.12			
19	Promoters and Promoter Group shareholding**									
	a) Pledged/Encumbered									
	- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL			
	- Percentage of shares (as a % of the total	NIL	NIL	NIL	NIL	NIL	NIL			
	- Percentage of shares (as a % of the total share	NIL	NIL_	NIL	NIL	NIL	NIL			
	b) Non-Encumbered									
	- Number of shares	4,18,281	4,18,281	4,18,281	4,18,281	4,18,281	4,18,28			
	- Percentage of shares (as a % of the total	100	100	100	100	100	100			
	- Percentage of shares (as a % of the total share	27 3	27.88	27.88	27.88	27.88	27.88			

Notes:

- The above Unaudited Financial Results for the quarter ended 31.12.2015 have been reviewed by the Audit Committee in their Meeting held on 21.01.2016 and approved by the Board of Directors of its Meeting held on 21.01.2016. The Limited Review Report of Auditors M/s Batliboi & Purohit was also taken on record by the Board in its Meeting.
- 2 The Company is not having any subsidary Company and these are standalone results.
- 3 Profit/(Loss) from discontinuing operations, if any, included in the above shall be disclosed seperately with details thereof.
- 4 A Company which presents Quarterly Financial Results in accordance with Ind AS 34 Interim Financial Reporting (applicable under Companies (Indian Accounting Standards) Rules, 2015) for the period covered by its first Ind AS Financial Statement shall comply with the requirements of Paragraph 32 of Ind AS 101-First time Adoption of Indian Accounting Standard
- 5 Investor's Complaints Pending at the Beginning No., Received during the Quarter Nil, Dispose Off -Nil, Remining at the End of Quarter Nil

SWA LADOR

For Chemo Pharma Laboratories Ltd.

Ashok Somani Director